BASF Ready to Snatch Seed Bargains As Rivals Sell off Assets
BASF will consider buying seed assets that rivals are putting on the block to win antitrust approval for tie-ups, saying bargain prices could persuade BASF to overcome its traditional reluctance to expand into the seeds industry.
"There are assets that will come to market for antitrust reasons and they might come at prices that are different from those that we have seen in the past. That's why we will look into it and see whether it makes sense for us," deputy Chief Executive Martin Brudermueller told journalists at a news conference at the group's headquarters.
"Seed assets are an option, not a must," he added.
Rival Bayer last month said it will sell its LibertyLink-branded seeds businesses, a key part of asset sales required to satisfy competition authorities looking at its $66 billion Monsanto deal.
You May Interested In
2026-10-09
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
BASF and Evonik Rumored Potential Acquisition or Merger
-
BASF and Thailand’s NEO Corporate Enter Joint Development Partnership in Personal Care
-
BASF Raises North American Nylon Products by $0.08/lb, Fourth Price Increase in Six Months
-
First New UV Filter in Nearly 27 Years: BASF's Tinosorb® S Approved by FDA, Marking a Historic Shift for the U.S. Sunscreen Market
-
Multiple Chemical Industry Leaders Post Strong H1 Earnings Growth as Sector Profitability Revives
-
The Crop Protection Patent Cliff Is Here
-
BASF's Intensified Moves from May to June: Plant Closures, Divestitures, and Transformation in Sync
-
EU Clears Carlyle's Acquisition of BASF's Coatings Business, but Demands Divestment of Nouryon's Polysulfide Assets: What Are the Underlying Risks?
-
BASF, Covestro, Huntsman Raise MDI Prices in North America Amid Global Supply Crunch
-
BASF Launches Global Expansion Plan for Aroma Ingredients
Recommend Reading
-
![Pfizer Sues Metsera and Novo Nordisk Over Rival Obesity Drug Strategy]()
Pfizer Sues Metsera and Novo Nordisk Over Rival Obesity Drug Strategy
-
![Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera]()
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
-
![Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera]()
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
-
![Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook]()
Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
-
![Merck and Eisai Halt Late-Stage Trial for Liver Cancer Therapy]()
Merck and Eisai Halt Late-Stage Trial for Liver Cancer Therapy
-
![Canada Issues Non-Compliance Notice to Dr. Reddy’s on Semaglutide Generic]()
Canada Issues Non-Compliance Notice to Dr. Reddy’s on Semaglutide Generic
-
![Strong Cost Support Drives Continued Strength in PTA Prices]()
Strong Cost Support Drives Continued Strength in PTA Prices
-
![Natural Rubber Market Trends Have Been Volatile and Consolidating Since July]()
Natural Rubber Market Trends Have Been Volatile and Consolidating Since July
-
![Calcium Hypochlorite: Properties, Uses, and Safety]()
Calcium Hypochlorite: Properties, Uses, and Safety
-
![Cost Support Boosts Acrylic Acid, High-level Supply and Demand Stalemate Leads to Sideways Movement]()
Cost Support Boosts Acrylic Acid, High-level Supply and Demand Stalemate Leads to Sideways Movement
